EDITClinical Trials•globenewswire•
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Sentiment:Positive (70)
Summary
(NASDAQ:EDIT) EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by globenewswire